STOCK TITAN
  1. Home
  2. News
  3. ANTX

AN2 Therapeutics Inc - ANTX STOCK NEWS

Welcome to our dedicated news page for AN2 Therapeutics (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AN2 Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AN2 Therapeutics's position in the market.

News
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
Rhea-AI Summary
AN2 Therapeutics, Inc. (ANTX) reports financial results for Q4 and year-end 2023, with a cash position of $134.5 million. Phase 2/3 trial (EBO-301) for TR-MAC ongoing, with Phase 2 topline results expected in summer 2024. Phase 3 enrollment paused for data analysis. Positive momentum in boron chemistry pipeline with licensing agreement for Chagas disease therapy and grant from Bill & Melinda Gates Foundation for TB and malaria treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.69%
Tags
earnings
-
News
AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
Rhea-AI Summary
AN2 Therapeutics, Inc. (ANTX) voluntarily pauses Phase 3 enrollment in the seamless Phase 2/3 clinical trial for epetraborole in treating MAC lung disease due to potentially lower efficacy than expected. The decision allows for further data review and recommendations from the independent Data Safety Monitoring Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-74.5%
Tags
clinical trial
-
News
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
Rhea-AI Summary
AN2 Therapeutics, Inc. (ANTX) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. Eric Easom, Co-Founder, President and CEO, will provide a corporate overview on February 14, 2024. The webcast can be accessed on the Investors section of the AN2 Therapeutics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
News
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
Rhea-AI Summary
ANTX: AN2 Therapeutics reports enrollment in Phase 3 of pivotal Phase 2/3 epetraborole study for MAC lung disease, presents new data at IDWeek 2023, and secures $150.2 million cash runway through summer 2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.08%
Tags
earnings
-
News
AN2 Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX) will participate in two upcoming investor conferences in November. Eric Easom, Co-Founder, President and CEO, will provide a corporate overview at the Stifel 2023 Healthcare Conference on November 15 at 3:00 p.m. ET and at the 6th Annual Evercore ISI HealthCONx Conference on November 29 at 8:45 a.m. ET. The presentations can be accessed on the AN2 Therapeutics website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
conferences
-
News
AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease
Rhea-AI Summary
AN2 Therapeutics receives exclusive license to advance development of boron-based small molecule for Chagas disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
News
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
Rhea-AI Summary
AN2 Therapeutics announces enrollment ongoing in Phase 3 trial of Epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
conferences
-
News
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria
Rhea-AI Summary
AN2 Therapeutics, Inc. has received a research grant from the Bill & Melinda Gates Foundation to develop treatments for tuberculosis and malaria. The funding will support the discovery of novel inhibitors using AN2's boron chemistry platform. This grant underscores AN2's commitment to addressing high unmet needs in global health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.26%
Tags
none
-
News
AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
Rhea-AI Summary
AN2 Therapeutics announces Phase 2 enrollment completion and initiation of Phase 3 for epetraborole, with topline results expected in summer 2024. Epetraborole has potential to become backbone therapy for MAC lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
clinical trial
News
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
Rhea-AI Summary
AN2 Therapeutics, Inc. announces pricing of underwritten offering of 7,777,778 shares of common stock at $9.00 per share, expected to raise approximately $70.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
offering
Stock ANTX logo
AN2 Therapeutics Inc

Nasdaq:ANTX

ANTX Rankings

#4526 Ranked by Market Cap
#1954 Ranked by Stock Gains
N/A Ranked by Dividends

ANTX Stock Data

73.53M
10.38M
25.94%
69.56%
0.92%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Menlo Park

About ANTX

an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.